Get started

Stocksignals

COINBASE at the bottom of the 20month Channel. Will it go lower?Coinbase (COIN) has been trading within a long-term Channel Up since the first week of January 2023 (almost 20 months). Within this time span, it has seen 4 corrections with the latter being the longest as we haven't seen a new High since the week of March 25 2024. Last Friday saw the week close on the strongest red 1W candle (-20%) since the 2022 Bear Cycle, as it failed to rebound on the 1W MA50 (blue trend-line). This on its own is a very pessimistic development, with the presence of only the 1W MA100 (green trend-line) remaining to offer support long-term. However, this Friday closing made an exact Higher Low at the bottom of the Channel Up, something we hadn't seen since the June 05 2023 1W candle. That was the candle that completed the longest (until the current one) correction on Coinbase. Both Bearish Legs have similar declines (-47% then and -48% now). The minimum % rise of a Bullish Leg within this Channel Up has been +146.82% (two times). As a result, as long as we close this week inside the Channel Up and ideally the 1W RSI remains above the 30.00 oversold barrier, we can expect a long-term bullish reversal on COIN with the start of the Channel's new Bullish Leg, with a minimum expectation being at $360.00 (+146.82% rally). ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NASDAQ:COINLong
by TradingShot
Marico can make merryMarico Limited, headquartered in Mumbai, Maharashtra, carries on business in branded consumer products. Marico manufactures and markets products with the brands such as Parachute, Parachute Advanced, Nihar, Nihar Naturals, Saffola, Hair & Care, Revive, Mediker, Livon, Set-wet, etc. Marico Limited CMP is 665.25. The positive aspects of the company are Dividend yield greater than sector dividend yield, Company with Low Debt, FII / FPI or Institutions increasing their shareholding and MFs increased their shareholding last quarter. The Negative aspects of the company are High PE (PE=56.7), High promoter stock pledges and Promoter decreasing their shareholding. Entry can be taken after closing above 668. Targets in the stock will be 682 AND 692. The long-term target in the stock will be 702 and 719. Stop loss in the stock should be maintained at Closing below 632 or 591 depending on your risk taking ability. Disclaimer: The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message.
NSE:MARICOLong
by Happy_Candles_Investment
Bajaj Electricals looks electrifying for the long termBajaj Electricals Limited was incorporated in July, 1938. The Company is engaged in business of consumer products (appliances, fans, lighting), EPC (illumination, power transmission and power distribution) and exports. Powered by a Pan-India presence and a market leading position in the industry, the Company functions through 20 branch offices which are duly supported by a chain of approximately over 700 distributors, 2.20 lakhs retail outlets and over 600 consumer care centres. The company has also a strong foothold in power transmission and distribution business. Bajaj Electricals Limited CMP is 1003.90. The positive aspects of the company are Mutual Funds Increased Shareholding in Past Month, Dividend yield greater than sector dividend yield and Company with No Debt. The Negative aspects of the company are High PE (PE=94.8), Low durability companies, Declining profits every quarter for the past 2 quarters. Entry can be taken after closing above 1022. Targets in the stock will be 1053, 1084, 1111 AND 1146. The long-term target in the stock will be 1189, 1274 and 1357. Stop loss in the stock should be maintained at Closing below 933 or 891 depending on your risk taking ability. Disclaimer: The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message.
NSE:BAJAJELECLong
by Happy_Candles_Investment
C3.AI is a great buy opportunity for the rest of the year.C3.ai (AI) has been trading within a Channel Down pattern for more than 1 year (since the August 01 2023 High) and yesterday it almost hit its bottom (Lower Lows trend-line). The 1D RSI breached below the 30.00 oversold barrier, and within this 1 year, it has always been a buy signal. However we can't rule out an extended consolidation or even a slightly Lower Low within those levels until the price recovers fully, but on the long-term and particularly until the end of the year, C3.ai presents a strong buy opportunity on the current level. The previous two Bullish Legs topped on the 0.785 Fibonacci retracement level, so our Target is 28.50 (marginally below it). ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:AILong
by TradingShot
Double-Top In PlayAs expected, SPY double-top looks to be playing out. I don't expect us to drop much lower than the pink ascending trendline. Maybe we'll touch that 200 dma before our full send. Let me remind you that the pink ascending tl is the neckline of a large cup and handle pattern on the bi-weekly, the target of which remains 650-700. This is still in play on the longer timeframe and as long as we don't break below the pink tl with confirmation on the weekly, I will start to buy back at or around the pink tl and down to the 200 dma. Batting 1000% thus far and hoping to keep it perfect.
AMEX:SPYShort
by stewdamus
1
TESLA broke above the 2-month Resistance and is aiming for $300Last month (August 15, see chart below) we gave a pull-back buy signal on Tesla (TSLA) and the price action swiftly responded with a August 28 Low and then rebound: The rebound was on the 1D MA200 (orange trend-line) and today we see a strong bullish break-out above the 1D MA50 (blue trend-line). This alone is enough to confirm the start of the next phase of the Bullish Leg, since the long-term pattern is a Channel Up, as closing above 228.00 will constitute a Higher High. Technically the structure is similar to the previous mid-Bullish Leg consolidation (April 30 - June 24), even the 1D MACD sequences between the two fractals are similar. In that sense we can't rule out some more ranged trading for September but on the long-term our Target remains unchanged. We expect the $300 level to break before November. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NASDAQ:TSLALong
by TradingShot
ROCKET LAB has started a new 9-month correction phase.Rocket Lab USA (RKLB) topped on August 19 after a more than +100% rise from the bottom that eventually reached the top of the Sine Wave count and as a result even though it failed to reach our $8.75 mark (Target 2), we will take profit on the last buy signal we issued (May 29, see chart below): As you can see by the Sine Waves, RKLB is repeating a 2-year cyclical pattern (since the June 30 2022 bottom), which every time it provides a buy opportunity that delivers a little over +100% return (3 times so far within this time span). Now that we got our +111% rise, we expect a new multi-month correction phase to start, initially in the form of a Channel Down (red). The previous correction phase lasted for 9 months and the one before for 10 months, before the +100% rallies commenced. As a result, we are far away from a buy opportunity at the moment and the best course of action is to short below even the 1D MA200 (orange trend-line). Our Target is $4.35, the middle of the High Volatility Zone, which is located just above the (green) Support Zone, where our next long-term buy will be. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NASDAQ:RKLBShort
by TradingShot
1
NETFLIX starting the 2nd bullish leg of its expansion phase.Netflix (NFLX) has been consolidating above the 1D MA50 (blue trend-line) since the August 20 High and is on the exact same level where during all previous Bullish Legs of the 2-year Channel Up, it ended the consolidation and moved to the 2nd rally of the expansion phase. This is also evident on the 1D RSI, which is about to start a Channel Down that in previous Legs it moved parallel with the price's 2nd rally. Our Target is $900.00 representing a +70.48% rise from April's low, which is the smallest rally recorded within the 2-year Channel Up, thus the more realistic target. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NASDAQ:NFLXLong
by TradingShot
S&P500 The Bull Cycle is still far from over!Six months ago while the market was undecided about whether or not the S&P500 (SPX) rally would continue, we presented a very useful multi-year chart on the 1M time-frame (February 27, see chart below), where we called for an extension of the uptrend, claiming confidently that the 'Bull Cycle is far from over': As you can see those who bought without fear have enjoyed so far more than +15% gains. What's even more impressive is the massive bullish reversal of the August candle, that managed to close the month in green, despite the early aggressive sell-off. This is a strong sign that the rally is far from over, but it's not the only one. The key here, and constitutes our main modification relative to the chart 6 months ago, is that the most accurate sell signal on a cyclical basis has been historically given after the 1M RSI breaks above the 70.00 overbought barrier and posts Lower Highs. This signal has had 100% accuracy in the past 10 years, effectively projecting the 2015, 2018 and 2022 corrections. The 1M RSI also has a Channel Down Resistance to consider but the Lower Highs signal should be top priority for investors to start selling. As a result, we expect the index to surpass the 6000 mark and even approach 6500, before we consider a cyclical selling sequence again. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
TVC:SPXLong
by TradingShot
5
Axis bank has a chance to ace it..Axis Bank Ltd. engages in banking and financial services. It provides financial solutions to retail, small and medium enterprises, government, and corporate businesses. It operates through the following segments: Treasury, Retail Banking, Corporate or Wholesale Banking, and Other Banking Business. The Other Banking Business segment encompasses para banking activities such as third party product distribution advisory and other banking transactions. Axis Bank Ltd. CMP is 1188.80. The positive aspects of the company are low Valuation (P.E. =13.8), Company with Zero Promoter Pledge, Increasing Revenue every Quarter for the past 8 Quarters, Mutual Funds Increased Shareholding over the Past Two Months, MFs increased their shareholding last quarter and Book Value per share Improving for last 2 years. The Negative aspects of the company are Poor cash generated from core business, declining Cash Flow from Operations and Increase in Provisions in the recent results. Entry can be taken after closing above 1191 Targets in the stock will be 1206, 1243 and 1270. The long-term target in the stock will be 1292, 1313 and 1337. Stop loss in the stock should be maintained at Closing below 1127. The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message.
NSE:AXISBANKLong
by Happy_Candles_Investment
Canara Bank Can start after consolidation.Canara Bank engages in the provision of commercial banking and financial services. It operates through the following segments: Treasury, Corporate or Wholesale Banking, Retail Banking, and Other Banking Business. Canara Bank CMP is 112.77 The positive aspects of the company are low Valuation (P.E. =6.5), Annual Profit Growth higher than Sector Profit Growth, Increasing profits every quarter for the past 2 quarters, Company with Zero Promoter Pledge, Mutual Funds Increased Shareholding over the Past Two Months and FII / FPI or Institutions increasing their shareholding. The share has good dividend yield of 2.9% at CMP. The Negative aspects of the company is that the stocks is underperforming their Industry Price. Entry can be taken after closing above 114 Targets in the stock will be 117 and 122. The long-term target in the stock will be 124 and 129. Stop loss in the stock should be maintained at Closing below 105. The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message.
NSE:CANBKLong
by Happy_Candles_Investment
RIVIAN giving highly accurate signals within this Channel Down.Rivian Automotive (RIVN) couldn't have been giving us more accurate signals since May (see charts below), as not only did we get a timely entry at the bottom (chart 1, May 17) but also sold at the very top (June 26 chart 2) of the Channel Down: Right now we face a technical similarity with September 2023, exactly 1 year ago, where the price failed to utilize the 1D MA50 (blue trend-line) as Support and started a new long-term Bearish sequence. However we do realize the potential long-term trend changing effect that a potential new cycle of interest rate cuts might have in two weeks, so again our trading plan will prepare for both scenarios with clear break-out signals and levels. Obviously as long as the price remains within the 2-year Channel Down, the trend is bearish and the action will be 'sell on every high'. The Sell Signal on the September 2023 fractal was given when the 1D RSI hit the 60.00 level (red arrow, Sep 14 2023). Naturally we will wait for another such trigger to sell and Target 10.55 on the 0.5 Fibonacci retracement level, which is where last year's sell signal bottomed (October 30 2023). If on the other hand, the price closes a 1W candle above the 1W MA100 (yellow trend-line), we will buy that clear long-term bullish break-out signal and Target 28.00 (just below Resistance 2). This could emerge as a Channel Up pattern. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NASDAQ:RIVN
by TradingShot
Powergrid can become PowerfulPower Grid Corp. of India Ltd. is a holding company, which engages in the power transmission business. It operates through the following segments: Transmission Services, Consultancy Services, and Telecom Services. It is a PSU company with high dividend yield of 3.3% at current market price. Power Grid Corp. of India Ltd. CMP is 337.40 The positive aspects of the company are moderate Valuation (P.E. =20), Company with Zero Promoter Pledge, MFs increased their shareholding last quarter, Growth in Quarterly Net Profit with increasing Profit Margin and The Negative aspects of the company are Inefficient use of shareholder funds - ROE declining in the last 2 years and Declining Net Cash Flow : Companies not able to generate net cash. Entry can be taken after closing above 343. Targets in the stock will be 348 and 356. The long-term target in the stock will be 364. Stop loss in the stock should be maintained at Closing below 328 or 291 depending on your risk taking ability. The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message.
NSE:POWERGRIDLong
by Happy_Candles_Investment
Ultratech may make not ultra but mild upward moves. UltraTech Cement Ltd. is a holding company, which engages in the manufacture and sale of cement and cement related products. Its products include ordinary portland cement, portland blast furnace slag cement, white cement, and ready mix concrete. UltraTech Cement Ltd. CMP is 11301.90. The positive aspects of the company are Company with Low Debt, Company with Zero Promoter Pledge, Book Value per share Improving for last 2 years. The Negative aspects of the company are high Valuation (P.E. =46.5), PE higher than Industry PE, MFs decreased their shareholding last quarter, Declining Net Cash Flow : Companies not able to generate net cash. Entry can be taken after closing above 11380. Targets in the stock will be 11524 and 11707. The long-term target in the stock will be 11893 and 12096. Stop loss in the stock should be maintained at Closing below 10922. The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message.
NSE:ULTRACEMCOLong
by Happy_Candles_Investment
SMCI This is honestly the last stand.Super Micro Computer Inc. (SMCI) suffered yet another brutal sell-off following the announcement of a delay in filing its 10-K annual report. This may prove to be a catastrophic one as technically not only did it fail exactly on its 1W MA50 (blue trend-line) but also saw the stock test the bottom of its multi-year parabolic support, the Higher Lows Zone since the week of July 05 2022. This was basically the last time the 1W MA100 (green trend-line) got tested with the current week coming the closest since then. The 1W MA100 last broke during the unexpected COVID flash crash in March 2020, so technically it is the stock's longest Support. If it fails to hold and SMCI closes a 1W candle below it, the long-term parabolic growth pattern is invalidated and we will risk testing the 1W MA200 (orange trend-line) at a price potentially around $250.00. If on the other hand the 1W MA100 holds (and we will need the news sentiment to drastically reverse in order to achieve that, something that currently can't be seen on the horizon), then we can see another +400% long-term rally, in which case we estimate a Target around $2000, the stock's next critical psychological growth level. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NASDAQ:SMCI
by TradingShot
2
TEVA Pharmaceutical is a BUY?As the excitement around AI continues to wane, concerns about a potential US recession grow, and the risks of a major conflict in the Middle East linger, Teva Pharmaceutical's stock is entering an accumulation phase above $18, signaling strong bullish sentiment. Why Wall Street's bullish in this drug company ? First, on July 31, Teva announced its financial results for the second quarter of 2024, demonstrating that the company remains resilient despite years of investor disappointment following the Allergan Generics acquisition and the loss of Copaxone exclusivity. However, over the past 18 months, under Richard Francis' leadership, the company has shown significant growth, with increasing revenue and profits in its European and US segments, the successful launch of biosimilars and Uzedy, and record sales of Austedo, its blockbuster treatment for certain neurological disorders. Alongside rising sales of generics, Teva has also accelerated the development of innovative medications, which could set new standards in treating schizophrenia and some chronic inflammatory diseases. For instance, on July 25, the company delighted investors by announcing that it had completed patient enrollment ahead of schedule in a Phase 2b clinical trial assessing the efficacy and safety of duvakitug for treating ulcerative colitis and Crohn's disease, driven by strong interest from healthcare professionals and patients. Teva Pharmaceutical's financial performance and 2024 outlook After years of challenges, the Teva revenue exceeded $4 billion once again, reaching $4.14 billion in the second quarter of 2024, a 7.4% year-on-year increase that surpassed consensus estimates by $114 million. Meanwhile, another critical financial metric, earnings per share aka EPS, exceeded my expectations despite rising costs associated with conducting expensive clinical trials for assessing the efficacy of Teva's biosimilars and experimental drugs targeting neurodegenerative and autoimmune disorders. The Israeli company's EPS reached $0.61 for the three months ending June 30, 2024, marking a 27.1% increase from the previous quarter and surpassing analysts' forecasts by six cents. What factors contribute to Teva Pharmaceutical's success? To answer this objectively, it's essential to examine not only the impact of sales from individual medications but also to delve deeper into how effectively the company's management is handling the development of each of Teva's business segments. We'll begin with the United States segment, which significantly influences Teva's financial standing. For the three months ending June 30, 2024, revenue in this segment reached $2.12 billion, reflecting an 11.5% year on year increase and a 22.3% rise from the previous quarter. First, Teva's revenue and profit growth were largely fueled by significant advancements in its generics business, despite facing stiff competition from companies like Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Perrigo (PRGO), and others in the market. In the second quarter, total sales of generic products reached approximately $1.03 billion, marking a 26.6% increase from the previous quarter. What factors led to the recovery of Teva's generics business? The resurgence of Teva's generics business in the U.S. was primarily driven by the launch of an interchangeable biosimilar to AbbVie's Humira (ABBV), rising demand for generic versions of Bristol-Myers Squibb's Revlimid (BMY), a major blockbuster for treating multiple myeloma, the generic version of Novo Nordisk's Victoza (NVO) for type 2 diabetes, and the expansion of its drug portfolio. The soaring sales of Copaxone and the strong performance of Austedo, which I analyzed in detail in a previous article, were also notable. Despite increasing competition in the U.S. tardive dyskinesia therapeutics market from Neurocrine Biosciences' (NBIX) Ingrezza, Austedo's demand continued to grow. Sales of the Austedo franchise reached $407 million in the second quarter of 2024, a 32.1% YOY increase, driven by expanded patient access and the FDA's late May approval of Austedo XR in four new tablet strengths, giving doctors more options for optimizing treatment regimens for adults with tardive dyskinesia and Huntington's disease-associated chorea. I also want to highlight Uzedy, a long-acting formulation of risperidone, as another key contributor to Teva's revenue growth. Although the company launched Uzedy in May 2023 and has not yet disclosed its sales figures, it has been approved for the treatment of schizophrenia. However, as evident from the chart below, the total number of prescriptions has been steadily increasing month over month. Teva Pharmaceutical estimates that its revenue from Uzedy will be around $80 million in 2024, exceeding my expectations by approximately $25 million. Despite ongoing growth in demand for this anti-CGRP migraine medication, its sales amounted to $42 million in the second quarter of 2024, a decrease of 6.7% compared to the previous quarter and 19.2% year-on-year. This decline was primarily due to an increase in sales allowances linked to a one-time event. Now, let's turn our attention to the company's Europe segment, which generates most of its revenue through sales of generics and biosimilars. For the three months ending June 30, 2024, sales in this segment reached approximately $1.21 billion, reflecting a 4.3% year-on-year increase, driven by new product launches and growing demand for Ajovy. However, sales of respiratory medications continue to face challenges due to a decline in cold and flu cases. As anticipated, demand for Copaxone is weakening, not only because of competition from generic versions but also due to the availability of more effective treatments for relapsing forms of multiple sclerosis, such as Bristol-Myers Squibb's Zeposia, Roche Holding's Ocrevus and TG Therapeutics' Briumvi (TGTX). Lastly, let's discuss the International Markets segment, which focuses on commercializing Teva's drugs across 35 countries, including Canada and Japan. In the second quarter, revenue for this segment was $593 million, representing a 2.6% YOY increase. However, the segment's profit dropped significantly to $73 million quarter over quarter, due to declining demand for Copaxone, increased R&D expenses, and higher sales and marketing costs related to the distribution of Austedo in China. The question arises: "Are there any positives?" The short answer is yes. Teva's revenue from generic drugs has been on an upward trend in recent years, with the exception of the fourth quarter of 2023. For the three months ending June 30, 2024, it reached $488 million, marking a 2% increase from the previous quarter. What is driving this sales growth? Despite challenges such as the weakening of foreign currencies like the Japanese yen, ruble, and Chinese yuan against the US dollar, increased competition in Japan, and ongoing inflationary pressures on the pharmaceutical industry, Teva’s management has successfully navigated these obstacles by expanding its medication portfolio and raising prices. Now lets talk about Risks Several risks could negatively impact Teva Pharmaceutical’s investment appeal in the medium to long term. At the end of July, Teva reported financial results for the second quarter of 2024, which not only exceeded analysts' expectations but also reinforced confidence in the effectiveness of the business strategies implemented by CEO Richard Francis. In addition to accelerating the recovery of the company's generics business, boosting sales of Austedo and Uzedy, and launching the Humira biosimilar in May, Teva also raised its full-year 2024 guidance. With a P/E ratio of 6.35x, which suggests the stock is trading at a discount compared to the broader healthcare sector, other positives include the reduction of Teva’s net debt by about $2 billion over the past 12 months, as well as year-over-year growth in gross and operating profits. To understand who truly holds control over Teva Pharmaceutical Industries Limited, it's crucial to examine the company's ownership structure. The largest share of ownership, approximately 69%, is held by institutional investors. This means that this group stands to experience the greatest potential for gains or losses, depending on the company's performance. The company has also accelerated the development of its product candidates under its "Pivot to Growth" program, which aims to strengthen its balance sheet and enhance its investment appeal by expanding its biosimilar portfolio and bringing potential best-in-class drugs for cancer, neurological, and autoimmune disorders to market. So TEVA Pharmaceutical is a BUY? YUP
NYSE:TEVALong
by moonypto
PALANTIR Correction starting. Short or wait to buy on that levelPalantir Technologies (PLTR) have been trading within a Channel Up since the May 04 2023 Low. Last week the price reached the pattern's top (Higher Highs trend-line) and technically we expect that to be the end of the recent Bullish Leg, as also indicated by the Sine Waves. Naturally we anticipate a medium-term pull-back in the form of a Bearish Leg. The previous 3 Bearish Legs have been under the form of Lower Highs that broke below the 1D MA50 (blue trend-line) and hit at least the 1D MA100 (green trend-line) before rebounding again into a new Bullish Leg. As a result, we expect to see at least a test of the 1D MA100, which short sellers can target $26.00. This is also above the minimum %correction we've seen inside this pattern (-25.90%). The strongest buy signal inside this long-term Channel Up is historically give when the 1D RSI hits the 35.85 - 30.20 Support Zone. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
PShort
by TradingShot